Table 3.
novel oral polio vaccine type 2 use in response supplementary immunization activities for cVDPV2s outbreaks by month and state, Nigeria during March‒December 2021
Outbreak response month | States | No. of States/No. of LGAs | No. of children reportedly vaccinated (million) |
---|---|---|---|
March 2021 | Bayelsa, Delta, Niger, Sokoto, Zamfara, FCT (1 area council, equivalent to a state LGA) | 6/91 | 7.8 |
April 2021 | Kebbi, Niger, Sokoto, Zamfara, and FCT (1 area council) | 5/84 | 6.2 |
April 2021 | Bayelsa and Delta | 2/28 | 10.1 |
May 2021 | Delta (5 LGAs) and Kebbi | 2/26 | 2.0 |
June 2021 | Abia, Akwa Ibom, Imo and Rivers | 4/98 | 5.2 |
June 2021 | Bauchi, Borno, Gombe, Jigawa, Kano, Katsina and Yobe | 7/180 | 14.8 |
July 2021 | Abia, Akwa Ibom, Bauchi, Borno, Gombe, Imo, Jigawa, Rivers, Kano, Katsina and Yobe | 11/278 | 21.2 |
August 2021 | Adamawa, Benue, FCT (5 area councils), Kaduna, Nasarawa, Plateau, Taraba and Zamfara | 8/133 | 11.7 |
September 2021 | Oyo and Sokoto | 2/56 | 3.3 |
September 2021 | Benue, FCT (5 area councils), Kaduna, Kebbi, Kwara, Nasarawa, Ogun, Osun, Plateau (14 LGAs), Taraba | 10/181 | 13.9 |
September 2021 | Adamawa, Lagos, Plateau (3 LGAs) | 3/44 | 6.5 |
October 2021 | Cross River, Edo, Kogi | 3/57 | 2.6 |
October 2021 | Anambra, Ebonyi, Enugu | 3/51 | 3.4 |
October 2021 | Sokoto | 1/23 | 1.5 |
October 2021 | Oyo | 1/33 | 2.2 |
October 2021 | Kebbi, Kwara, Ogun, Osun | 4/87 | 5.4 |
October 2021 | Kogi, Lagos | 2/41 | 6.3 |
November 2021 | Zamfara | 1/14 | 4.9 |
November 2021 | Edo | 1/18 | 0.60 |
November 2021 | Anambra | 1/21 | 2.1 |
November 2021 | Ebonyi, Enugu | 2/30 | 4.6 |
December 2021 | Bauchi (5 LGAs), Cross River, Gombe (3 LGAs), Katsina (6 LGAs) | 4/32 | 2.1 |
December 2021 | Jigawa (8 LGAs), Yobe (2 LGAs) | 2/10 | 0.85 |
December 2021 | Borno (10 LGAs), Kano (12 LGAs), Ondo | 3/41 | 3.4 |
December 2021 | Ekiti | 1/16 | 0.5 |
December 2021 | BayelsaOndo | 1/8 | 0.48 |
Abbreviation - LGA: local government area; FCT: federal capital territory; cVDPV: circulating vaccine-derived poliovirus